Results 81 to 90 of about 115,954 (269)

Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers

British Journal of Clinical Pharmacology, EarlyView.
Aims In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated
Alexandre O. Gérard, Diane Merino, Marc Labriffe, Fanny Rocher, Delphine Viard, Laurence Zemori, Thibaud Lavrut, Erik M. Donker, Joost D. Piët, Jean‐Paul Fournier, Milou‐Daniel Drici, Alexandre Destere   +11 more
wiley   +1 more source

Avelumab first‐line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial

Cancer Medicine
Background Avelumab first‐line (1 L) maintenance is a standard of care for advanced urothelial carcinoma (aUC) based on the JAVELIN Bladder 100 phase 3 trial, which showed that avelumab 1 L maintenance + best supportive care (BSC) significantly prolonged
Juliane Manitz, Aslihan Gerhold‐Ay, Pascal Kieslich, Parantu Shah, Thomas Mrowiec, Karin Tyroller   +5 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma

Clinical and Translational Science
Like other monoclonal antibodies, immune checkpoint inhibitors may be immunogenic in some patients, potentially affecting pharmacokinetics (PKs) and clinical outcomes.
Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao   +12 more
doaj   +1 more source

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Janie E. Rogers, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +9 more
wiley   +1 more source

Precise and Accurate Counts and Viability Measurements Across Multiple Cell Lines Using the Muse™ Cell Count & Viability Assay

BioTechniques, 2012
EMD Millipore
doaj   +1 more source

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

CPT: Pharmacometrics & Systems Pharmacology
Several investigational agents are under evaluation in systemic lupus erythematosus (SLE) clinical trials but quantitative frameworks to enable comparison of their efficacy to reference benchmark treatments are lacking. To benchmark SLE treatment effects
Kosalaram Goteti, Ramon Garcia, William R. Gillespie, Jonathan French, Lena Klopp‐Schulze, Ying Li, Cristina Vazquez Mateo, Sanjeev Roy, Oliver Guenther, Lisa Benincosa, Karthik Venkatakrishnan   +10 more
doaj   +1 more source

Long‐term outcomes of microsurgical interdental papilla reconstruction: 13‐year and 18‐year case follow‐ups

Clinical Advances in Periodontics, EarlyView.
Abstract Background Loss of the interdental papilla compromises esthetics, speech, and hygiene, significantly affecting quality of life and psychological well‐being. Reconstruction has long been considered unpredictable, particularly in Cairo RT3 cases with advanced interproximal bone loss.
Katsuhiko Akiyama
wiley   +1 more source

Ten‐year follow‐up of bilateral gingival recession treatment: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background This work aims to present a 10‐year follow‐up of a young patient who underwent treatment with collagen matrix (CM) combined with enamel matrix derivative (EMD) for bilateral gingival recessions in the maxillary canine region. Methods The patient, a 25‐year‐old woman, presented with bilateral Cairo type 1 recessions.
Luiz C. L. Marques‐Junior, Milena S. Irie, Edgar Daniel Vargas‐Quiroga, Mario Taba‐Jr, Atila V. V. Nobre   +4 more
wiley   +1 more source